GGrantIndex
Sort

326,823 grants matching clinical trial

Primary Immune Deficiency Treatment Consortium

$1,846,474
Jennifer Maxwell Puck · University Of California, San Francisco · U54 · FY2021 · AI

Hematopoietic Chimerism after Stem Cell Allografts

$1,846,366
Rainer F. Storb · Fred Hutchinson Cancer Research Center · P01 · FY2014 · CA

Penn PET Addiction Center of Excellence (Penn PACE)

$1,846,343
Robert H Mach · University Of Pennsylvania · P30 · FY2021 · DA

Primary Immune Deficiency Treatment Consortium

$1,846,257
Jennifer Maxwell Puck · University Of California, San Francisco · U54 · FY2023 · AI

Primary Immune Deficiency Treatment Consortium

$1,846,257
Jennifer Maxwell Puck · University Of California, San Francisco · U54 · FY2022 · AI

Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma

$1,846,248
Matthew L Meyerson · Dana-Farber Cancer Inst · P01 · FY2017 · CA

Development of Adrb3 Antagonists for the Treatment of Pain

$1,846,202
Andrea G Nackley · Duke University · R61 · FY2023 · NS

Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma

$1,846,173
Matthew L Meyerson · Dana-Farber Cancer Inst · P01 · FY2020 · CA

Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma

$1,846,173
Matthew L Meyerson · Dana-Farber Cancer Inst · P01 · FY2018 · CA

Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma

$1,846,173
Matthew L Meyerson · Dana-Farber Cancer Inst · P01 · FY2021 · CA

Innate Immunity: Elucidation/Modulation - Cancer Therapy

$1,846,087
Ohio State University · P01 · FY2003 · CA

Population Genetics Analysis Program: Immunity to Vaccines and Infections

$1,845,910
Richard A. Kaslow · University Of Alabama At Birmingham · N01 · FY2011 · AI

Clinical Research Support Core

$1,845,830
Francis Sessions Cole · Harvard Medical School · U2C · FY2025 · NS

Aging Well, Sleeping Efficiently

$1,845,550
Timothy H. Monk · University Of Pittsburgh At Pittsburgh · P01 · FY2012 · AG

Deciphering the efficacy of posttransplant cyclophosphamide in BMT

$1,845,452
Christopher Kanakry · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primates

$1,845,438
Tatsuo Kawai · Massachusetts General Hospital · R01 · FY2025 · AI

I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes

$1,845,433
Laura J Esserman · University Of California, San Francisco · P01 · FY2020 · CA

Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens

$1,845,039
William C Hahn · Dana-Farber Cancer Inst · U01 · FY2017 · CA

CURE CTU

$1,845,017
Stephen A Spector · University Of California, San Diego · UM1 · FY2025 · AI

CLINICAL TRIAL FOR COMMUNITY-ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS

$1,845,000
Andrew Boulter · University Of California, San Francisco · N01 · FY2014 · AI

Functional MRI Method Development

$1,844,995
Peter Bandettini · National Institute Of Mental Health · ZIA · FY2009 · MH

Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages

$1,844,691
Barton F Haynes · Duke University · U19 · FY2019 · AI

Noroviruses and Epidemic Gastroenteritis

$1,844,686
Kim Y. Green · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

Quality Assurance Review Center

$1,844,678
Thomas J Fitzgerald · Univ Of Massachusetts Med Sch Worcester · U10 · FY2010 · CA

Mechanisms of non-classical multidrug resistance in cancer

$1,844,598
Michael Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA